Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vesatolimod in HIV-1 Controllers
NCT03060447Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- May 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in human immunodeficiency virus type 1 infection (HIV-1) comparing Vesatolimod with Placebo (2 arms). Primary endpoint: Percentage of Participants Experiencing Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Emergent Adverse Events (TEAEs) up to 33 months. Started May 2017; status: completed.
02
Drugs
vesatolimod
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03060447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03060447.